Key facts
- It has raised $48.0M; the latest was Later Stage VC ($3.0M) in Apr 2026.
- Notable investors include Collaborative Fund, Spectra Investments, Start-Up Chile, Kaszek, The Yield Lab — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for PhageLab
- ·The full record, as it builds
Funding rounds
No funding rounds for PhageLab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PhageLab
Developer of antibiotic substitutes designed for the livestock industry. The company's medicines are designed to be used in industrial facilities as a food-grade additive, that can recognize pathogen bacteria specifically, without affecting the commensal flora, enabling food industries to selectively eliminate pathogenic bacteria with ease and increase productivity.
- Sector
- Materials and Resources
- HQ
- Santiago, Chile
- Founded
- 2010
- Employees
- 92
- Website
- phage-lab.com/
- Ownership
- Privately Held (backing)
PhageLab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhageLab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhageLab in its N-PORT filings yet. We sweep new filings monthly.